PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
A Glaviano, ASC Foo, HY Lam, KCH Yap, W Jacot… - Molecular cancer, 2023 - Springer
Abstract The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal
transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell …
transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell …
The CDK4/6 inhibitor revolution—A game-changing era for breast cancer treatment
L Morrison, S Loibl, NC Turner - Nature Reviews Clinical Oncology, 2024 - nature.com
Abstract Cyclin-dependent kinase (CDK) 4/6 inhibition in combination with endocrine
therapy is the standard-of-care treatment for patients with advanced-stage hormone receptor …
therapy is the standard-of-care treatment for patients with advanced-stage hormone receptor …
Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer
A Bardia, X Hu, R Dent, K Yonemori… - … England Journal of …, 2024 - Mass Medical Soc
Background Outcomes in patients with hormone receptor–positive metastatic breast cancer
worsen after one or more lines of endocrine-based therapy. Trastuzumab deruxtecan has …
worsen after one or more lines of endocrine-based therapy. Trastuzumab deruxtecan has …
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer
Background Inavolisib is a highly potent and selective inhibitor of the alpha isoform of the
p110 catalytic subunit of the phosphatidylinositol 3-kinase complex (encoded by PIK3CA) …
p110 catalytic subunit of the phosphatidylinositol 3-kinase complex (encoded by PIK3CA) …
[HTML][HTML] 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)
F Cardoso, S Paluch-Shimon, E Schumacher-Wulf… - The breast, 2024 - Elsevier
This manuscript describes the Advanced Breast Cancer (ABC) international consensus
guidelines updated at the last two ABC international consensus conferences (ABC 6 in …
guidelines updated at the last two ABC international consensus conferences (ABC 6 in …
Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
Endocrine therapy (ET) with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) is currently the
standard first-line treatment for most patients with hormone receptor (HR) positive, human …
standard first-line treatment for most patients with hormone receptor (HR) positive, human …
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
Combining the selective AKT inhibitor, capivasertib, and SERD, fulvestrant improved PFS in
a Phase III clinical trial (CAPItello-291), treating HR+ breast cancer patients following …
a Phase III clinical trial (CAPItello-291), treating HR+ breast cancer patients following …
Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of …
A Bardia, J Cortés, FC Bidard, P Neven… - Clinical Cancer …, 2024 - aacrjournals.org
Purpose: Elacestrant significantly prolonged progression-free survival (PFS) with
manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with …
manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with …
Metastatic ER+ breast cancer: mechanisms of resistance and future therapeutic approaches
F Raheem, SA Karikalan, F Batalini, A El Masry… - International Journal of …, 2023 - mdpi.com
Endocrine therapy is the main treatment for hormone receptor-positive (HR+) breast cancer.
However, advanced tumors develop resistance to endocrine therapy, rendering it ineffective …
However, advanced tumors develop resistance to endocrine therapy, rendering it ineffective …
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
Anti-oestrogen-based therapies, often combined with a CDK4/6 inhibitor, are the current
standard-of-care first-line therapy for patients with advanced-stage hormone receptor …
standard-of-care first-line therapy for patients with advanced-stage hormone receptor …